Elan Says It Has Fixed The Biogen Breach, And Gives J&J a $115 Million Discount
This article was originally published in The Pink Sheet Daily
Executive Summary
The three-way drama heads toward a resolution -- if Biogen Idec accepts Elan's moves.
You may also be interested in...
Rich Enough to Reduce Debt, Elan Again Pulls Drug-Delivery Unit Off the Block
Armed with cash from its blockbuster Alzheimer's deal with J&J, the drug maker says it can wait indefinitely to sell its profitable contract business.
Rich Enough to Reduce Debt, Elan Again Pulls Drug-Delivery Unit Off the Block
Armed with cash from its blockbuster Alzheimer's deal with J&J, the drug maker says it can wait indefinitely to sell its profitable contract business.
J&J Braces For Health Care Reform Hit, But Can "Accommodate" Impact
J&J's 2010 sales will be $400 million to $500 million lower due to health care reform, although J&J didn't significantly lower 2010 earnings as a result.